Glaxosmithkline Biologicals Sa

The Brigham and Women's Hospital, Inc.

Pfizer Ireland Pharmaceuticals

Utrecht University

Ralph Leon Biemans

Jan Poolman

Pierre Duvivier

Philippe Denoel

Dominique Boutriau

Carine Capiau

Philippe Vincent Hermand

Marcelle Paulette Van Mechelen

Nathalie Marie-Josephe Garcon

Ollivier Francis Nicolas Gavard

Annick Vandercammen

Vincent Weynants

Martine Petronella Bos

Emmanuel Mertens

Karine Goraj

Carine Goraj

Tomas Maira-Litran

Christiane Feron

Nathalie Marie-Josephe Garçon

Elisabeth Marie Monique Bertaud

Nicolas Jean Benoit Moniotte

Laurent Bernard Jean Strodiot

Abdelatif Elouahabi

Jan Tommassen

Dominique Glaxosmithkline Biologicals Boutriau

Francois-Xavier Jacques Berthet

Marcell Paulette Van Mechelen

Jan Poolmann

Ollivier Francis Gavard

Pierre Glaxosmithkline Biologicals Sa Duvivier

Jan Glaxosmithkline Biologicals sa Poolman

Philippe Glaxosmithkline Biologicals Sa Denoel

Carine Glaxosmithkline Biologicals Sa Capiau

Olivier Francis Nicolas Gavard

The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, the present invention relates to sizedserotype 6A capsular polysaccharides, in particularserotype 6A capsular polysaccharides having the average size (e.g. M) of theserotype 6A capsular polysaccharide is between 100-1000 kDa, suitably conjugated to a carrier protein.

Vaccine

The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, an immunogenic composition for infants is provided comprising a multivalentvaccine comprising 2 or more capsular saccharide conjugates from different serotypes, wherein the composition comprises a serotype 22F saccharide conjugate. Such a vaccine may be used in infant populations to reduce the incidence of elderly pneumococcal disease such as exacerbations of COPD and/or IPD.

Pneumococcal capsular saccharide conjugate vaccine

The present application discloses an immunogenic composition comprisingcapsular polysaccharides from at least one of serogroups A, C, W135 and Y conjugated to a carrier protein to produce acapsular polysaccharide conjugate, wherein the average size of eachpolysaccharide is above 50 kDa.

Immunogenic composition

The present invention relates to a process for conjugation of an antigen.

Conjugation process

The present invention discloses an immunogenic composition comprisingcapsular saccharide conjugates from serotypes 19A and 19F wherein 19A is conjugated to a first bacterial toxoid and 19F is conjugated to a second bacterial toxoid. Vaccines, methods of making vaccines and uses of the vaccines are also described.

[object Object]

The present application discloses an immunogenic composition comprising at least 2 differentcapsular saccharides, wherein one or more is/are selected from a first group consisting of MenA, MenC, MenY and MenW which is/are conjugated through a linker to a carrier protein(s), and one or more different saccharides is/are selected from a second group consisting of MenA, MenC, MenY and MenW which is/are directly conjugated to a carrier protein(s).

present application discloses an immunogenic composition comprisingcapsular polysaccharides from at least one of serogroups A, C, W135 and Y conjugated to a carrier protein to produce acapsular polysaccharide conjugate, wherein the average size of eachpolysaccharide is above 50 kDa.

The present application relates to an immunogenic composition comprising at least 2 conjugates ofcapsular saccharide and protein carrier, wherein said conjugates comprise at least 2 differentcapsular saccharides selected from the group consisting of MenA, MenC, MenY and MenW, wherein at least one capsular saccharide is conjugated to a protein carrier with a saccharide:protein ratio (w/w) between 1:2-1:5, and wherein at least one different capsular saccharide is conjugated to a protein carrier with a saccharide:protein ratio (w/w) between 5:1-1:1.99.

The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, a multivalentimmunogenic composition is provided with various conjugated capsular saccharides from differentserotypes conjugated to 2 or more different carrier proteins, where the composition comprises serotype 19F capsular saccharide conjugated to diphtheria toxoid (DT) or CRM197, optionally wherein 19F is the only saccharide in the composition conjugated to diphtheria toxoid (DT) or CRM197.

Pneumoccal polysacchride conjugate vaccine

The present invention relates to an immunogenic composition comprisingcapsular saccharide conjugates from serotypes 19A and 19F wherein 19A is conjugated to a first bacterial toxoid and 19F is conjugated to a second bacterial toxoid. Methods of making and uses thereof are also described.

The present application discloses an immunogenic composition comprising at least 2 differentcapsular saccharides, wherein one or more is/are selected from a first group consisting of MenA, MenC, MenY and MenW which is/are conjugated to a protein carrier(s) wherein the saccharide:protein ratio (w/w) is between 1:2-1:5, and one or more different saccharides is/are selected from a second group consisting of MenA, MenC, MenY and MenW which is/are conjugated to a protein carrier(s) wherein the saccharide:protein ratio (w/w) is between 5:1-1:1.99.

The present application discloses an immunogenic composition comprising a Hib saccharide conjugate, at least one additional bacterial, for example, saccharide conjugate(s), and a further antigen selected from the group consisting of whole cell pertussis and hepatitis B surface antigen, wherein the saccharide dose of the Hib saccharide conjugate is less than 5 &#x3bc;g.

Growing community of inventors

Rixensart, Belgium

Ralph Leon Biemans